Search Result

Results for "

delayed gastric emptying

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) ACSL Family (2) Adrenergic Receptor (1) Amylin Receptor (3) CaSR (1) CGRP Receptor (1) Cholinesterase (ChE) (5) CRFR (1) Dopamine Receptor (1) Fluorescent Dye (1) GABA Receptor (1) GCGR (1) GLP Receptor (3) Isotope-Labeled Compounds (1) Proton Pump (1) Reference Standards (1)
By Research Areas:	Inflammation/Immunology (9) Metabolic Disease (16) Neurological Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0171

Antipyrine 3 Publications Verification Phenazone; Phenazon	Fluorescent Dye GABA Receptor	Metabolic Disease Inflammation/Immunology
Antipyrine (Phenazone) is an orally active antipyretic and analgesic. Antipyrine can be used as a probe agent for oxidative agent metabolism. Antipyrine also delays gastric emptying (GE) in rats .

HY-P1070A

Amylin, amide, human TFA DAP amide, human TFA	Amylin Receptor	Metabolic Disease
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-P1070

Amylin, amide, human DAP amide, human	Amylin Receptor	Metabolic Disease
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-121467

Acotiamide Z-338 free base; YM443 free base	Cholinesterase (ChE)	Metabolic Disease Inflammation/Immunology
Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC₅₀ of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .

HY-B2155

Acotiamide monohydrochloride trihydrate	Cholinesterase (ChE)	Metabolic Disease Inflammation/Immunology
Acotiamide monohydrochloride trihydrate is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with IC₅₀ of 1.79 μM. Acotiamide monohydrochloride trihydrate can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide monohydrochloride trihydrate has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .

HY-139201E

Poly-D-lysine hydrobromide (MW 150000-300000) PDLHB (MW 150000-300000)	CaSR 5-HT Receptor	Metabolic Disease
Poly-D-lysine hydrobromide (MW 150000-300000) is a synthetic polymer composed of D-lysine residues and is one of the most widely used matrices in neural cell culture applications. Poly-D-lysine hydrobromide (MW 150000-300000) can be used as a non-specific cell adhesion enhancer. Poly-D-lysine hydrobromide (MW 30000-70000) is an orally active CaSR agonist peptide that indirectly activates the 5-HT₃ receptor signaling pathway, delaying gastric emptying and thereby slowing the rate at which glucose enters the small intestine and is absorbed .

HY-P11320

Davalintide	Amylin Receptor CGRP Receptor	Metabolic Disease
Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC₅₀ = 0.04 nM), calcitonin receptor (IC₅₀ = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC₅₀ = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC₅₀ = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes .

HY-121467A

Acotiamide hydrochloride Z-338; YM443	Cholinesterase (ChE)	Others Metabolic Disease Inflammation/Immunology
Acotiamide hydrochloride is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC₅₀ of 1.79 μM. Acotiamide hydrochloride can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide hydrochloride has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .

HY-P3130

Stresscopin-related peptide (human)	CRFR	Neurological Disease Inflammation/Immunology
Stresscopin-related peptide (human) is a specific ligand for the type 2 CRH receptor. Stresscopin-related peptide (human) suppresses food intake, delayed gastric emptying and decreases heat-induced edema. Stresscopin-related peptide (human) maintains homeostasis after stress, and can be used in the research of stress-related diseases .

HY-B2195

Aldioxa	Adrenergic Receptor	Metabolic Disease
Aidioxa has the ability to improve delayed gastric emptying in rats. It can partially improve delayed gastric emptying caused by clonidine or restraint stress. The allyltoin part of Aidioxa restores gastric emptying activity by antagonizing α-2 adrenergic receptors. Its aluminum hydroxide part is involved in restoring gastric compliance. Aidioxa can improve both delayed gastric emptying and impaired gastric compliance, both of which play an important role in functional dyspepsia (FD). Aidioxa is a candidate agent for inhibiting FD.

HY-75424A

2-(Trifluoromethyl)cinnamic acid	Proton Pump	Inflammation/Immunology
2-(Trifluoromethyl)cinnamic acid is a cinnamic acid derivative that inhibits the proton pump (H ⁺/K ⁺-ATPase), thereby reducing gastric acid secretion. 2-(Trifluoromethyl)cinnamic acid also improves delayed gastric emptying and can be used in research on gastric diseases such as acute gastritis and gastric ulcers .

HY-176770

GLP-1R agonist 34	GLP Receptor	Metabolic Disease
GLP-1R agonist 34 (Compound 1) is an orally active small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R agonist 34 promotes insulin secretion, inhibits glucagon release, and delays gastric emptying, thereby effectively lowering blood glucose levels. GLP-1R agonist 34 is promising for research of metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-171850

GLP-1R modulator-1	GLP Receptor	Metabolic Disease Inflammation/Immunology
GLP-1R modulator-1 (Compound 384) is an orally active, potent selective glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R modulator-1 activates G-protein coupled signaling, elevates intracellular cAMP levels, promotes insulin secretion, delays gastric emptying and suppresses appetite. GLP-1R modulator-1 is promising for research of type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-171851

GLP-1R agonist 32	GCGR	Metabolic Disease
GLP-1R agonist 32 (Compound 111) is an orally active and highly potent GLP-1R agonist with an EC₅₀ value of 0.017 nM. GLP-1R agonist 32 exerts glucose-regulating activity by activating GLP-1R to stimulate cAMP production, promoting insulin secretion, inhibiting glucagon release, and delaying gastric emptying. GLP-1R agonist 32 is promising for research of type 2 diabetes, obesity, and related metabolic disorders .

HY-121467S1

Acotiamide-d4 Z-338 free base-d4; YM443 free base-d4	Isotope-Labeled Compounds Cholinesterase (ChE)	Metabolic Disease Inflammation/Immunology
Acotiamide-d₄ (Z-338 (free base)-d₄) is deuterium labeled Acotiamide. Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC₅₀ of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .

HY-128386

Cinitapride monotartrate	5-HT Receptor Dopamine Receptor	Neurological Disease
Cinitapride monotartrate is a 5-HT_1A and 5-HT₄ agonist. Cinitapride monotartrate is also a 5-HT_2A and D₂ antagonist. Cinitapride monotartrate can be used for the research of functional dyspepsia .

HY-B2155R

Acotiamide monohydrochloride trihydrate (Standard)	Reference Standards Cholinesterase (ChE)	Metabolic Disease Inflammation/Immunology
Acotiamide (monohydrochloride trihydrate) (Standard) is the analytical standard of Acotiamide (monohydrochloride trihydrate). This product is intended for research and analytical applications. Acotiamide monohydrochloride trihydrate is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with IC₅₀ of 1.79 μM. Acotiamide monohydrochloride trihydrate can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide monohydrochloride trihydrate has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .

HY-186095

LP-911888	ACSL Family	Metabolic Disease
LP-911888 is an orally active ACSL5/ACSL1 inhibitor, with IC₅₀ values of 1 nM and 3 nM against mouse and human ACSL5, and IC₅₀ values of 2 nM and 9 nM against mouse and human ACSL1, respectively. LP-911888 inhibits intestinal triglyceride uptake; it also reduces body weight and food consumption in diet-induced obese mice, and delays gastric emptying by activating the ileal brake pathway. LP-911888 can be used in studies of diet-induced obesity .

HY-186096

LP-856866	ACSL Family GLP Receptor	Metabolic Disease
LP-856866 is an orally active ACSL5 inhibitor, with IC₅₀ values of 8 nM and 4 nM against mouse and human ACSL5, respectively, and IC₅₀ values of 6 nM and 17 nM against mouse and human ACSL1, respectively. LP-856866 induces delayed gastric emptying, promotes GLP-1 release, reduces food intake, decreases body weight and body fat mass, preserves lean body mass, improves glucose homeostasis, enhances insulin sensitivity, reduces hepatic lipid accumulation, and lowers serum triglyceride and total cholesterol levels. LP-856866 is applicable to research on diet-induced obesity .

Cat. No.	Product Name	Type

HY-139201E

Poly-D-lysine hydrobromide (MW 150000-300000) PDLHB (MW 150000-300000)	Biochemical Assay Reagents
Poly-D-lysine hydrobromide (MW 150000-300000) is a synthetic polymer composed of D-lysine residues and is one of the most widely used matrices in neural cell culture applications. Poly-D-lysine hydrobromide (MW 150000-300000) can be used as a non-specific cell adhesion enhancer. Poly-D-lysine hydrobromide (MW 30000-70000) is an orally active CaSR agonist peptide that indirectly activates the 5-HT₃ receptor signaling pathway, delaying gastric emptying and thereby slowing the rate at which glucose enters the small intestine and is absorbed .

Poly-D-lysine hydrobromide (MW 150000-300000)

PDLHB (MW 150000-300000)

Biochemical Assay Reagents

Poly-D-lysine hydrobromide (MW 150000-300000) is a synthetic polymer composed of D-lysine residues and is one of the most widely used matrices in neural cell culture applications. Poly-D-lysine hydrobromide (MW 150000-300000) can be used as a non-specific cell adhesion enhancer. Poly-D-lysine hydrobromide (MW 30000-70000) is an orally active CaSR agonist peptide that indirectly activates the 5-HT₃ receptor signaling pathway, delaying gastric emptying and thereby slowing the rate at which glucose enters the small intestine and is absorbed .

Cat. No.	Product Name	Target	Research Area

HY-P1070A

Amylin, amide, human TFA DAP amide, human TFA	Amylin Receptor	Metabolic Disease
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-P1070

Amylin, amide, human DAP amide, human	Amylin Receptor	Metabolic Disease
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-P11320

Davalintide	Amylin Receptor CGRP Receptor	Metabolic Disease
Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC₅₀ = 0.04 nM), calcitonin receptor (IC₅₀ = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC₅₀ = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC₅₀ = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes .

HY-P3130

Stresscopin-related peptide (human)	CRFR	Neurological Disease Inflammation/Immunology
Stresscopin-related peptide (human) is a specific ligand for the type 2 CRH receptor. Stresscopin-related peptide (human) suppresses food intake, delayed gastric emptying and decreases heat-induced edema. Stresscopin-related peptide (human) maintains homeostasis after stress, and can be used in the research of stress-related diseases .

Cat. No.	Product Name	Chemical Structure

HY-121467S1

Acotiamide-d4
Acotiamide-d₄ (Z-338 (free base)-d₄) is deuterium labeled Acotiamide. Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC₅₀ of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .

Acotiamide-d4

Acotiamide-d₄ (Z-338 (free base)-d₄) is deuterium labeled Acotiamide. Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC₅₀ of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.